Skip to main content
. 2013 Winter;24(4):217–238. doi: 10.1155/2013/781410

TABLE 8.

Treatment protocols for hepatitis C (HCV) genotype 1 in HIV-HCV coinfection

Treatment-naive Relapser Partial responder Null responder
Boceprevir
HIV-HCV coinfected
  SVR rate (versus PegIFN α2b + RBV) 63% versus 27%
  Relapse rate 3%
  Duration of PegIFN α2b + RBV Fixed 48-week duration
  Duration of HCV PI 44 weeks
  PegIFN α2b + RBV lead-In Yes: 4 weeks
HCV monoinfected
  SVR rate (versus PegIFN α2b + RBV) 63% (n=368) versus 38% (n=363) 69% (n=72/105) versus 29% (n=15/51) 40% (n=23/57) versus 7% (n=2/29) 40% (n=47) (no control)
  Relapse rate (versus PegIFN α2b + RBV) 9% versus 22% 14% (n=12/83) versus 32% (n=7/22) 18% (n=5/28) versus 33% (n=1/3) 14% (no control)
  Duration of PegIFN α2b + RBV Response guided (28 versus 48 weeks) Response-guided (36 versus 48 weeks)* Response-guided (36 versus 48 weeks)* Fixed 48-week duration
  PegIFN α2b + RBV lead-In Yes: 4 weeks Yes: 4 weeks Yes: 4 weeks Yes: 4 weeks
Telaprevir
HIV-HCV coinfected
  SVR rate (versus PegIFN α2a + RBV) 74% versus 45%
  Relapse rate
  Duration of PegIFN α2a + RBV Fixed 48-week duration
  Duration of HCV PI 12 weeks
  PegIFN α2a + RBV lead-In No
HCV monoinfected
  SVR rate (versus PegIFN α2a + RBV) 75% (n=271/363) versus 44% (n=158/361) 86% (n=245/286) versus 24% (n=16/68) 57% (n=55/97) versus 15% (n=4/27) 31% (n=46/147) versus 5% (n=2/37)
  Relapse rate (versus PegIFN α2a + RBV) 9% (n=27/314) versus 28% (n=64/229) 3% (n=19/278) versus 63% (n=27/43) 20% (n=14/71) versus 0% (n=0/4) 24% (n=15/62) versus 50% (n=2/4)
  Duration of PegIFN α2a + RBV Response-guided (24 or 48 weeks) Response-guided (24 versus 48 weeks) Fixed 48-week duration Fixed 48-week duration
  Duration of HCV PI 12 weeks 12 weeks 12 weeks 12 weeks
  PegIFN α2a + RBV lead-in No No No No
*

If cirrhotic, then 48 weeks fixed duration,

Interim results from rollover study (132). PegIFN α2a Pegylated interferon alfa-2a; PI Protease inhibitor; RBV Ribavirin; SVR Sustained virological response